Reliable Detection and Quantification of Protein Impurities
Automatic and reliable detection and quantification of low concentrated protein impurities down to 0.05% and below with the Agilent 2100 Bioanalyzer!
The Agilent 2100 Bioanalyzer together with the Agilent High Sensitivity Protein 250 Kit allows you to reliably detect and quantify low concentrated impurities next to massive main components – down to 0.05% and below. This meets the ICH guideline Q3B(R2): Impurities in New Drug Products! Reporting threshold 0.05% for a maximum daily dose >1g.
The Agilent 2100 Bioanalyzer provides:
- sensitivity and linear dynamic range – silver stain sensitivity down to 1 pg/μL of labeled protein on chip and 4 orders of magnitude in linear dynamic range
- fast results – complete automated analysis of 10 samples in 30 minutes
- reproducibility – qualitative, user-independent and digital data
- ease of use – standardized assay, pre-packaged reagent kits
- 21 CFR Part 11 compliance – validated reagents and software plus Agilent compliance services to meet all GMP/GLP needs
The High Sensitivity Protein 250 kit provides the first microfluidic assay for protein detection in the low picogram range. Therefore, the kit is suited excellent to solve typical protein QA/QC questions and to comply with ICH and FDA guidelines – in the Bioanalyzer-like, fast and reproducible way.
Learn more!Receive a free Protein QC application CD!
Contact
Agilent Technologies, Inc.
Life Sciences and Chemical Analysis Group
5301 Stevens Creek Boulevard
Santa Clara, CA 95051-7201
USA
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
